Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Usha MenonAleksandra Gentry-MaharajMatthew BurnellAndy RyanJatinderpal K KalsiNaveena SinghAnne DawnayDame Lesley FallowfieldAlistair J McGuireStuart CampbellSteven J SkatesMahesh K B ParmarIan J JacobsPublished in: Health technology assessment (Winchester, England) (2023)
Long-term follow-up UKCTOCS (2015-2020) - National Institute for Health and Care Research (NIHR HTA grant 16/46/01), Cancer Research UK, and The Eve Appeal. UKCTOCS (2001-2014) - Medical Research Council (MRC) (G9901012/G0801228), Cancer Research UK (C1479/A2884), and the UK Department of Health, with additional support from The Eve Appeal. Researchers at UCL were supported by the NIHR UCL Hospitals Biomedical Research Centre and by MRC Clinical Trials Unit at UCL core funding (MR_UU_12023).
Keyphrases
- healthcare
- papillary thyroid
- clinical trial
- public health
- squamous cell
- mental health
- cross sectional
- quality improvement
- human health
- randomized controlled trial
- health information
- type diabetes
- magnetic resonance
- risk assessment
- magnetic resonance imaging
- young adults
- cardiovascular events
- childhood cancer
- coronary artery disease
- tertiary care
- contrast enhanced
- computed tomography
- chronic pain